T Cell–Mediated Humoral Immune Responses to Type 3 Capsular Polysaccharide ofStreptococcus pneumoniae

T cells control the generation of nanomolar-affinity anti-glycan antibodies

(2017) Zinaida Polonskaya et al.   JOURNAL OF CLINICAL INVESTIGATION

Carbohydrates as T-cell antigens with implications in health and disease

(2016) Lina Sun et al.   GLYCOBIOLOGY

Pneumococcal Capsules and Their Types: Past, Present, and Future

(2015) K. Aaron Geno et al.   CLINICAL MICROBIOLOGY REVIEWS

Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?

(2014) A. Torres et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012

(2013) Walter H.B. Demczuk et al.   CANADIAN JOURNAL OF MICROBIOLOGY

Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial

(2013) Ron Dagan et al.   CLINICAL INFECTIOUS DISEASES

Novel Strategies for Development of Next-Generation Glycoconjugate Vaccines

(2013) Fikri Avci   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Carbohydrates and T cells: A sweet twosome

(2013) Fikri Y. Avci et al.   SEMINARS IN IMMUNOLOGY

O-mannosylation of the Mycobacterium tuberculosis Adhesin Apa Is Crucial for T Cell Antigenicity during Infection but Is Expendable for Protection

(2013) Subhadra Nandakumar et al.   PLoS Pathogens

Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine

(2012) William C. Gruber et al.   Annals of the New York Academy of Sciences

Development of a Fourfold Multiplexed Opsonophagocytosis Assay for Pneumococcal Antibodies against Additional Serotypes and Discovery of Serological Subtypes in Streptococcus pneumoniae Serotype 20

(2012) Robert L. Burton et al.   Clinical and Vaccine Immunology

Isolation of carbohydrate-specific CD4+ T cell clones from mice after stimulation by two model glycoconjugate vaccines

(2012) Fikri Y Avci et al.   Nature Protocols

The design of semi-synthetic and synthetic glycoconjugate vaccines

(2011) Paolo Costantino et al.   Expert Opinion on Drug Discovery

A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design

(2011) Fikri Y Avci et al.   NATURE MEDICINE

Healthcare utilization and cost of pneumococcal disease in the United States

(2011) Susan S. Huang et al.   VACCINE

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

(2010) Dorothee M. Kieninger et al.   VACCINE

How Bacterial Carbohydrates Influence the Adaptive Immune System

(2009) Fikri Y. Avci et al.   Annual Review of Immunology

Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM197 conjugate vaccine co-localizes with MHC II on the antigen processing cell surface

(2009) Zengzu Lai et al.   VACCINE

Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease

(2009) W.P. Hausdorff et al.   VACCINE

Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae

(2008) Caroline L. Trotter et al.   VACCINE